Samsung Bioepis reported a decline in both revenue and operating profit for the second quarter of this year compared to the same period last year. However, the company continues to show growth in its first-half results.
Samsung Epise Holdings announced on July 24 that Samsung Bioepis recorded revenue of 392.2 billion won and an operating profit of 86.6 billion won in the second quarter. These figures represent decreases of 2.2% and 3.6%, respectively, from the previous year, attributed to changes in the supply schedule of key products and increased investment in research and development (R&D). During the same period, net profit rose by 72.1% to 106.7 billion won.
For the first half of the year, the company reported revenue of 847.1 billion won and an operating profit of 230.6 billion won, both reflecting a 6% increase compared to the same period last year.
Samsung Bioepis stated, "The increasing demand for products in major markets such as Europe and the United States is expected to be reflected in our performance in the second half of the year. We anticipate continuing our business success in the global market this year."
The company is intensifying its efforts to penetrate global markets. In May, it launched the Eylea biosimilar in Europe, expanding its direct sales products in the region to five. In the United States, it has begun selling the Prolia biosimilar, and in Japan, it has entered the market with its first product, the Stelara biosimilar.
Samsung Bioepis is also enhancing the competitiveness of its pipeline. Last month, it released global Phase 1 and Phase 3 clinical trial results for its immuno-oncology biosimilar candidate, SB27, demonstrating equivalence to the original drug in primary endpoints such as pharmacokinetics and efficacy.
Additionally, Samsung Bioepis is the first company among those developing a Keytruda biosimilar to announce global Phase 3 clinical trial results.
The company is accelerating its new drug development efforts. The antibody-drug conjugate (ADC) candidate SBE303 entered global Phase 1 clinical trials in March, while the follow-up candidate SBE313 is currently in preclinical development.
Samsung Bioepis is also pursuing long-acting obesity treatments and open innovation-based new drug development to secure mid- to long-term growth drivers.
Meanwhile, Samsung Epise Holdings has maintained its forecast that Samsung Bioepis's annual revenue growth rate will exceed 10% compared to last year's figure of 1.67 trillion won, despite uncertainties in the global market.
Samsung Epise Holdings announced on July 24 that Samsung Bioepis recorded revenue of 392.2 billion won and an operating profit of 86.6 billion won in the second quarter. These figures represent decreases of 2.2% and 3.6%, respectively, from the previous year, attributed to changes in the supply schedule of key products and increased investment in research and development (R&D). During the same period, net profit rose by 72.1% to 106.7 billion won.
For the first half of the year, the company reported revenue of 847.1 billion won and an operating profit of 230.6 billion won, both reflecting a 6% increase compared to the same period last year.
Samsung Bioepis stated, "The increasing demand for products in major markets such as Europe and the United States is expected to be reflected in our performance in the second half of the year. We anticipate continuing our business success in the global market this year."
The company is intensifying its efforts to penetrate global markets. In May, it launched the Eylea biosimilar in Europe, expanding its direct sales products in the region to five. In the United States, it has begun selling the Prolia biosimilar, and in Japan, it has entered the market with its first product, the Stelara biosimilar.
Samsung Bioepis is also enhancing the competitiveness of its pipeline. Last month, it released global Phase 1 and Phase 3 clinical trial results for its immuno-oncology biosimilar candidate, SB27, demonstrating equivalence to the original drug in primary endpoints such as pharmacokinetics and efficacy.
Additionally, Samsung Bioepis is the first company among those developing a Keytruda biosimilar to announce global Phase 3 clinical trial results.
The company is accelerating its new drug development efforts. The antibody-drug conjugate (ADC) candidate SBE303 entered global Phase 1 clinical trials in March, while the follow-up candidate SBE313 is currently in preclinical development.
Samsung Bioepis is also pursuing long-acting obesity treatments and open innovation-based new drug development to secure mid- to long-term growth drivers.
Meanwhile, Samsung Epise Holdings has maintained its forecast that Samsung Bioepis's annual revenue growth rate will exceed 10% compared to last year's figure of 1.67 trillion won, despite uncertainties in the global market.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.